WO2000070047A3 - Molecules completes exprimees dans des tissus humains - Google Patents

Molecules completes exprimees dans des tissus humains Download PDF

Info

Publication number
WO2000070047A3
WO2000070047A3 PCT/US2000/013299 US0013299W WO0070047A3 WO 2000070047 A3 WO2000070047 A3 WO 2000070047A3 US 0013299 W US0013299 W US 0013299W WO 0070047 A3 WO0070047 A3 WO 0070047A3
Authority
WO
WIPO (PCT)
Prior art keywords
full
human tissues
molecules expressed
flexht
length molecules
Prior art date
Application number
PCT/US2000/013299
Other languages
English (en)
Other versions
WO2000070047A2 (fr
Inventor
Henry Yue
Y Tom Tang
Preeti Lal
Roopa Reddy
Sajeev Batra
Mariah R Baughn
Junming Yang
Yalda Azimzai
Dyung Aina M Lu
Janice Au-Young
Leo L Shih
Original Assignee
Incyte Genomics Inc
Henry Yue
Y Tom Tang
Preeti Lal
Roopa Reddy
Sajeev Batra
Mariah R Baughn
Junming Yang
Yalda Azimzai
Dyung Aina M Lu
Au Young Janice
Leo L Shih
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc, Henry Yue, Y Tom Tang, Preeti Lal, Roopa Reddy, Sajeev Batra, Mariah R Baughn, Junming Yang, Yalda Azimzai, Dyung Aina M Lu, Au Young Janice, Leo L Shih filed Critical Incyte Genomics Inc
Priority to EP00935966A priority Critical patent/EP1179065A2/fr
Priority to JP2000618453A priority patent/JP2002543839A/ja
Priority to AU51346/00A priority patent/AU5134600A/en
Priority to CA002373191A priority patent/CA2373191A1/fr
Publication of WO2000070047A2 publication Critical patent/WO2000070047A2/fr
Publication of WO2000070047A3 publication Critical patent/WO2000070047A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)

Abstract

L'invention se rapporte à des molécules complètes exprimées dans des tissus humains, désignées par le terme FLEXHT, et à des polynucléotides qui identifient et codent pour FLEXHT. L'invention se rapporte également à des vecteurs d'expression, des cellules hôtes, des anticorps, des agonistes et des antagonistes. L'invention se rapporte également à des méthodes permettant d'analyser l'expression de gènes humains, les relations génétiques et la variabilité génétique, et de diagnostiquer, traiter ou prévenir des troubles associés à l'expression de FLEXHT.
PCT/US2000/013299 1999-05-14 2000-05-12 Molecules completes exprimees dans des tissus humains WO2000070047A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00935966A EP1179065A2 (fr) 1999-05-14 2000-05-12 Molecules completes exprimees dans des tissus humains
JP2000618453A JP2002543839A (ja) 1999-05-14 2000-05-12 ヒト組織に発現する完全長分子
AU51346/00A AU5134600A (en) 1999-05-14 2000-05-12 Full-length molecules expressed in human tissues
CA002373191A CA2373191A1 (fr) 1999-05-14 2000-05-12 Molecules completes exprimees dans des tissus humains

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US31193799A 1999-05-14 1999-05-14
US31194099A 1999-05-14 1999-05-14
US31189499A 1999-05-14 1999-05-14
US09/311,940 1999-05-14
US09/311,937 1999-05-14
US09/311,894 1999-05-14

Publications (2)

Publication Number Publication Date
WO2000070047A2 WO2000070047A2 (fr) 2000-11-23
WO2000070047A3 true WO2000070047A3 (fr) 2001-06-28

Family

ID=27405538

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/013299 WO2000070047A2 (fr) 1999-05-14 2000-05-12 Molecules completes exprimees dans des tissus humains

Country Status (5)

Country Link
EP (1) EP1179065A2 (fr)
JP (1) JP2002543839A (fr)
AU (1) AU5134600A (fr)
CA (1) CA2373191A1 (fr)
WO (1) WO2000070047A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057203A1 (fr) * 2000-02-01 2001-08-09 Taisho Pharmaceutical Co.,Ltd. NOUVEAU GENE TIG104α ET PROTEINE TIG104α CODEE PAR CE GENE
WO2001077393A2 (fr) * 2000-04-10 2001-10-18 Zymogenetics, Inc. Procede de detection de troubles neurologiques
WO2002040684A2 (fr) * 2000-11-14 2002-05-23 Bayer Aktiengesellschaft Regulation de phosphatase acide pourpre d'origine humaine
US20040053292A1 (en) * 2000-11-15 2004-03-18 Jurg Tschopp Proteins and dna sequences underlying these proteins used for treating inflammations
CA2436661A1 (fr) * 2001-01-30 2002-08-08 Regeneron Pharmaceuticals, Inc. Nouvelles molecules d'acide nucleique et polypeptidiques
US20020187522A1 (en) * 2001-03-06 2002-12-12 Yan Luo DNA encoding human Cid1
WO2003029426A2 (fr) * 2001-10-03 2003-04-10 Immunex Corporation Polypeptides des cytokines humaine et murine
EP2006687A1 (fr) * 2007-06-20 2008-12-24 Commissariat A L'energie Atomique Procédé de test dýun sujet dont on pense quýil a ou quýil est prédisposé à de lýasthme, des allergies, une maladie atopique ou une sensibilisation atopique

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0197592A1 (fr) * 1985-04-01 1986-10-15 Stichting Vrienden Van De Stichting Dr. Karl Landsteiner Préparation du facteur von Willebrand humain par un ADN recombinant
EP0679716A1 (fr) * 1993-11-12 1995-11-02 Kenichi Matsubara Signature genique
WO1999038972A2 (fr) * 1998-01-28 1999-08-05 Chiron Corporation Genes humains et produits ii d'expression genique
WO1999064594A2 (fr) * 1998-06-11 1999-12-16 Chiron Corporation Genes et produits d'expression genique regules de façon differentielle lors du cancer de la prostate

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0197592A1 (fr) * 1985-04-01 1986-10-15 Stichting Vrienden Van De Stichting Dr. Karl Landsteiner Préparation du facteur von Willebrand humain par un ADN recombinant
EP0679716A1 (fr) * 1993-11-12 1995-11-02 Kenichi Matsubara Signature genique
WO1999038972A2 (fr) * 1998-01-28 1999-08-05 Chiron Corporation Genes humains et produits ii d'expression genique
WO1999064594A2 (fr) * 1998-06-11 1999-12-16 Chiron Corporation Genes et produits d'expression genique regules de façon differentielle lors du cancer de la prostate

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL EBI; 25 August 1995 (1995-08-25), FUJIWARA ET AL.: "Human fetal brain cDNA 5' -end GEN-111H12", XP002148068 *
DATABASE EMBL EBI; 3 April 1997 (1997-04-03), STRAUSBERG ET AL.: "National Cancer Institute, Cancer Anatomy Project (CGAP)", XP002148067 *

Also Published As

Publication number Publication date
CA2373191A1 (fr) 2000-11-23
AU5134600A (en) 2000-12-05
JP2002543839A (ja) 2002-12-24
EP1179065A2 (fr) 2002-02-13
WO2000070047A2 (fr) 2000-11-23

Similar Documents

Publication Publication Date Title
WO2002002634A3 (fr) Molécules de matrice extracellulaire et d'adhésion cellulaire
WO2001012662A3 (fr) Proteines associees a la membrane
WO2002046383A3 (fr) Molecules de modification et de maintenance proteiques
WO2001007628A3 (fr) Synthetases humaines
WO1998058052A3 (fr) Maladies associees a des proteines kinases
WO2000018922A8 (fr) Proteines humaines associees a des glucides
WO2000012703A3 (fr) Molecules associees au transport de proteines
WO2000017355A3 (fr) Proteines humaines associees au cytosquelette
WO2001020004A3 (fr) Proteines phosphatase et proteines kinase
WO2000044900A3 (fr) Proteines liant des acides nucleiques
WO2000005374A3 (fr) Molecules associees a une proliferation cellulaire
WO2000070047A3 (fr) Molecules completes exprimees dans des tissus humains
WO2001007471A3 (fr) Proteines du cycle et de proliferation cellulaires
WO2000028032A3 (fr) Proteines du recepteur de surface des cellules humaines
WO2001044448A3 (fr) Proteines d'oxydoreductase humaines
WO2000020604A3 (fr) Molecules d'oxydoreductase
WO2001032888A3 (fr) Molecules humaines de la transferase
WO1999038981A3 (fr) Molecules de proteine kinase humaines
WO1999041373A3 (fr) Molecules humaines associees au transport
WO2001042285A3 (fr) Matrice extracellulaire et molecules d'adherence cellulaire
WO2001019860A3 (fr) Proteines associees a la differenciation cellulaire
WO1999049037A3 (fr) Molecules apparentees a la proteine-phosphatase
WO1998059041A3 (fr) Nucleotides kinases apparentees aux maladies
WO2000008155A3 (fr) Proteines associees a un recepteur humain
WO2001083524A3 (fr) Proteines du metabolisme de l'arn

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2373191

Country of ref document: CA

Ref country code: CA

Ref document number: 2373191

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 618453

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000935966

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000935966

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000935966

Country of ref document: EP